Study of O-glycosylation characteristics in cystic fluid of pancreatic cystic neoplasms

doi:10.3877/cma.j.issn.2095-7157.2025.03.005

Abstract

Abstract:

Objective

To explore the characteristics of O-glycosylation in the cystic fluid of pancreatic cystic neoplasms (PCNs), providing a direction for further exploring new biomarkers and studying the mechanism of PCNs.

Methods

The cystic fluid of serous cystadenoma (SCN), mucinous cystic neoplasm (MCN), and intraductal papillary mucinous neoplasm (IPMN) was detected by liquid chromatography- tandem mass spectrometry (LC-MS/MS). Bioinformatics analysis technology was used to analyze the differential glycoproteins, preliminarily exploring the possible mechanism of PCNs.Meanwhile, combined with clinical data and current research status, the potential biomarkers were explored.

Results

According to the mass spectrometry detection, there were significant differences in protein O-glycosylation between IPMN, SCN, and MCN.A total of 156 up-regulated and 17 down-regulated differential glycopeptides were discovered between IPMN and SCN.Meanwhile, between IPMN and MCN, there were 145 up-regulated glycopeptides and 2 down-regulated.The results of gene ontology (GO) analysis and Kyoto encyclopedia of genes and genomes (KEGG) analysis showed that the differential glycoproteins were mainly located in the extracellular matrix, zymogen granule membrane, Golgi cavity, blood microparticles, etc., which were mainly involved in the maintenance of gastrointestinal epithelium, negative regulation of inflammatory response, acute phase response, intracellular iron homeostasis, and other biological processes.The main related pathways include complement and coagulation cascade, pancreatic secretion, IL-17 signaling pathway, neuroactive ligand-receptor interaction, ECM-receptor interaction, cholesterol metabolism etc.Finally, eight characteristic glycoproteins were selected.

Conclusion

(1) There were differences in the O-glycosylation of protein among IPMN, MCN, and SCN; (2) The mechanism of PCNs may be related to immune response, signal transduction, gastrointestinal epithelial maintenance, and pancreatic secretion, etc.; (3) MUC-5AC, MUC-5B, MUC-2, FN, Elastase-3A, Elastase- 3B, Alpha-2-M and PL-RP2 could be used as potential biomarkers to identify different types of PCNs.

Key words: Pancreatic cystic neoplasms, Cystic fluid, Glycoproteomics, O-glycosylation

Bingqian Cheng, Ningli Chai, Chen Du, Fei Gao, Huikai Li, Xiuxue Feng, Yunyun Zhao, Enqiang Linghu. Study of O-glycosylation characteristics in cystic fluid of pancreatic cystic neoplasms[J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2025, 12(03): 190-196.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhwcnjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-7157.2025.03.005

https://zhwcnjdzzz.cma-cmc.com.cn/EN/Y2025/V12/I03/190

Figures/Tables 6

References 30

[1]	Chandwani R，Allen PJ.Cystic Neoplasms of the Pancreas[J]．Annu Rev Med，2016，67(1)：45-57.
[2]	Gardner TB，Park WG，Allen PJ.Diagnosis and Management of Pancreatic Cysts[J]．Gastroenterology，2024，167(3)：454-468.
[3]	Farrell JJ，Fernández-del Castillo C．Pancreatic Cystic Neoplasms: Management and Unanswered Questions[J]．Gastroenterology，2013, 144(6)：1303-1315.
[4]	Farrell JJ.Prevalence，Diagnosis and Management of Pancreatic Cystic Neoplasms：Current Status and Future Directions[J]．Gut Liver，2015, 9(5)：571-589.
[5]	Ardeshna DR，Cao T，Rodgers B，et al.Recent advances in the diagnostic evaluation of pancreatic cystic lesions[J]．World J Gastroenterol, 2022，28(6)：624-634.
[6]	Li SY，Wang ZJ，Pan CY，et al.Comparative Performance of Endoscopic Ultrasound-Based Techniques in Patients With Pancreatic Cystic Lesions：A Network Meta-Analysis[J]．Am J Gastroenterol，2023, 118(2)：243-255.
[7]	Thomas DR，Scott NE.Glycoproteomics：growing up fast[J]．Curr Opin Struct Biol，2021，68(1)：18-25.
[8]	Li J，Zhao T，Li J，et al.Precision N-glycoproteomics reveals elevated LacdiNAc as a novel signature of intrahepatic cholangiocarcinoma [J]．Mol Oncol，2022，16(11)：2135.
[9]	Costa J，Streich L，Pinto S，et al.Exploring Cerebrospinal Fluid IgG N-Glycosylation as Potential Biomarker for Amyotrophic Lateral Sclerosis[J]．Mol Neurobiol，2019，56(8)：5729-5739.
[10]	Cao Z，Maupin K，Curnutte B，et al.Specific Glycoforms of MUC5AC and Endorepellin Accurately Distinguish Mucinous from Nonmucinous Pancreatic Cysts[J]．Mol Cell Proteomics，2013，12(10): 2724-2734.
[11]	Haab BB，Porter A，Yue T，et al.Glycosylation Variants of Mucins and CEACAMs as Candidate Biomarkers for the Diagnosis of Pancreatic Cystic Neoplasms[J]．Ann Surg，2010，251(5)：937-945.
[12]	Cui M，Hu Y，Zhang Z，et al.Cyst fluid glycoproteins accurately distinguishing malignancies of pancreatic cystic neoplasm[J]．Signal Transduct Target Ther，2023，8(1)：406-415.
[13]	Nieminen H，Nummela P，Satomaa T，et al.N-glycosylation in non-invasive and invasive intraductal papillary mucinous neoplasm[J]．Sci Rep，2023，13(1)：13191-13202.
[14]	刘璐瑶，秦洪强，叶明亮．完整糖基化肽段的富集与质谱解析新技术研究进展[J]．色谱，2021，39(10)：1045-1054.
[15]	孟凡刚，孟雅冰．蛋白质组学与应用[M]．北京：化学工业出版社，2022.
[16]	沈百荣，黄健．蛋白质组信息学[M]．北京：科学出版社，2023.
[17]	高春芳．糖基化：未来可期的新型疾病标志物[J]．中华检验医学杂志，2022，45(4)：315-317.
[18]	Wang Y，Sun Y，Feng J，et al.Glycopatterns and Glycoproteins Changes in MCN and SCN：A Prospective Cohort Study[J]．Biomed Res Int，2019，2019：2871289.
[19]	Carrara S，Cangi MG，Arcidiacono PG，et al.Mucin Expression Pattern in Pancreatic Diseases：Findings From EUS-Guided Fine-Needle Aspiration Biopsies[J]．Am J Gastroenterol，2011，106(7)：1359-1363.
[20]	Kwon RS，Simeone DM.The Use of Protein-Based Biomarkers for the Diagnosis of Cystic Tumors of the Pancreas[J]．Int J Proteomics, 2011，2011：1-9.
[21]	Furukawa T，Klöppel G，Volkan Adsay N，et al.Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study[J]．Virchows Arch，2005，447(5)：794-799.
[22]	Furukawa T，Hatori T，Fujita I，et al.Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas[J]．Gut，2011，60(4)：509-516.
[23]	Dalton CJ，Lemmon CA.Fibronectin: Molecular Structure, Fibrillar Structure and Mechanochemical Signaling[J]．Cells，2021，10(9)：2443.
[24]	Topalovski M，Brekken RA.Matrix control of pancreatic cancer：new insights into fibronectin signaling[J]．Cancer Letters，2015，381(1): 252-258.
[25]	Paulo JA，Kadiyala V，Banks PA，et al.Mass Spectrometry-Based (GeLC-MS/MS) Comparative Proteomic Analysis of Endoscopically (ePFT) Collected Pancreatic and Gastroduodenal Fluids[J]．Clin Transl Gastroenterol，2012，3(5)：e14-e23.
[26]	Moore PC，Cortez JT，Chamberlain CE，et al.Elastase 3B mutation links to familial pancreatitis with diabetes and pancreatic adenocarcinoma [J]．J Clin Invest，2019，129(11)：4676-4681.
[27]	Zhu G，Fang Q，Zhu F，et al.Structure and Function of Pancreatic Lipase-Related Protein 2 and Its Relationship With Pathological States[J]．Front Genet，2021，12：693538.
[28]	Cater JH，Wilson MR，Wyatt AR.Alpha-2-Macroglobulin，a Hypochlorite-Regulated Chaperone and Immune System Modulator [J]．Oxid Med Cell Longev，2019，2019：5410657.
[29]	Tomihari A，Kiyota M，Matsuura A，et al.Alpha 2-macroglobulin acts as a clearance factor in the lysosomal degradation of extracellular misfolded proteins[J]．Sci Rep，2023，13(1)：4680.
[30]	Jaldín-Fincati JR，Actis Dato V，Díaz NM，et al.Activated α2-Macroglobulin Regulates LRP1 Levels at the Plasma Membrane through the Activation of a Rab10-dependent Exocytic Pathway in Retinal Müller Glial Cells[J]．Sci Rep，2019，9(1)：13234.

参数	值
酶切类型	Trypsin
固定修饰类型	Carbamidomethyl(C)
可变修饰类型	M Oxidation(15.995Da); Acetyl (Protein N-terminal)
前体离子质量偏差容忍范围	± 15 ppm
碎片离子质量偏差容忍范围	± 0.02 Da
最大酶漏切位点	2

参数	值
酶切类型	Trypsin
固定修饰类型	Carbamidomethyl(C)
可变修饰类型	M Oxidation(15.995Da); Acetyl (Protein N-terminal)
前体离子质量偏差容忍范围	± 15 ppm
碎片离子质量偏差容忍范围	± 0.02 Da
最大酶漏切位点	2

特征	数值
性别
男	6(30)
女	14(70)
年龄(岁，±s)	48.8±10.1
病变部位
胰头部	7(35)
胰体部	4(20)
胰尾部	9(45)
PCNs类型
SCN	8(40)
MCN	8(40)
IPMN	4(20)

特征	数值
性别
男	6(30)
女	14(70)
年龄(岁，±s)	48.8±10.1
病变部位
胰头部	7(35)
胰体部	4(20)
胰尾部	9(45)
PCNs类型
SCN	8(40)
MCN	8(40)
IPMN	4(20)

Please choose a citation manager

Content to export